

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED**

**博智國際藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1149)**

## **RESIGNATION AND APPOINTMENT OF EXECUTIVE DIRECTORS**

### **RESIGNATION OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Broad Intelligence International Pharmaceutical Holdings Limited (the “**Company**”) announces that Mr. Chong Hoi Fung (“**Mr. Chong**”) has resigned as an executive director of the Company with effect from 3 February 2010 to pursue his other career opportunities.

Mr. Chong has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board has accepted his resignation with effect from 3 February 2010.

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that Mr. Lin Supeng (“**Mr. Lin**”) has been appointed as an executive director of the Company with effect from 3 February 2010.

Mr. Lin, aged 26, holds a degree of Bachelor of Science in 數學與應用數學 (信息與計算科學) (Mathematics and Applied Mathematics (Information and Computational Science)) from 深圳大學 (Shenzhen University), the People's Republic of China, and a degree of Master of Information Technology from The University of Queensland, Australia. Mr. Lin is knowledgeable in computer programming and is experienced in software development project management.

Mr. Lin is currently the Chief Officer of the Technical Department of 深圳市安芯數字發展有限公司 (Shenzhen Anxin Digital Development Co., Limited) (“**Anxin**”), an indirect wholly-owned subsidiary of the Company, and is responsible for the supervision and management of the said department, including development of system software and application software. Save as aforesaid and being an executive director of the Company, Mr. Lin does not hold any other position in the Company or any of its subsidiaries.

Mr. Lin has not entered into any service contract with the Company. He is entitled to receive an annual director's fee of HK\$30,000, which is determined by the Board with reference to his duties and responsibilities and the prevailing market conditions. Mr. Lin is not appointed for a specific term and he shall hold office until the next annual general meeting of the Company, and thereafter shall be subject to retirement by rotation and eligible for re-election at future annual general meetings of the Company in accordance with the articles of association of the Company.

Mr. Lin has not held any directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas or other major appointments or professional qualifications over the last three years.

Mr. Lin does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company and does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as aforesaid, there are no other matters concerning the foregoing appointment of director that are required to be disclosed pursuant to any of the requirements set out in Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange, and the Company is not aware of any other matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

## **APPRECIATION**

The Board would like to take this opportunity to thank Mr. Chong for his valuable contribution to the Company, and welcome Mr. Lin to the Board.

By Order of the Board  
**Broad Intelligence International Pharmaceutical Holdings Limited**  
**Mr. Zhong Houtai**  
*Chairman*

Hong Kong, 3 February 2010

*As at the date of this announcement, the executive directors of the Company are Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Sun Daquan and Mr. Lin Supeng, and the independent non-executive directors of the Company are Mr. Cheung Chuen, Mr. Pei Renjiu and Mr. Li Kai Ming.*